Publications

Nature communications

A network analysis to identify mediators of germline-driven differences in breast cancer prognosis.

16-01-2020

Nature

Loss of p53 triggers WNT-dependent systemic inflammation to drive breast cancer metastasis.

01-08-2019

NPJ breast cancer

Breast adipocyte size associates with ipsilateral invasive breast cancer risk after ductal carcinoma in situ.

22-03-2021

Molecular oncology

Epigenetic and transcriptional analysis reveals a core transcriptional program conserved in clonal prostate cancer metastases.

11-02-2021

Genome medicine

Correction to: A role for the unfolded protein response stress sensor ERN1 in regulating the response to MEK inhibitors in KRAS mutant colon cancers.

10-02-2021

Nature medicine

Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial.

01-12-2020

Clinical cancer research : an official journal of the American Association for Cancer Research

Functional Categorization of BRCA1 Variants of Uncertain Clinical Significance in Homologous Recombination Repair Complementation Assays.

01-09-2020

Radiology

Radiogenomic Analysis of Breast Cancer by Linking MRI Phenotypes with Tumor Gene Expression.

01-08-2020

Scientific reports

Epigenetic profiling demarcates molecular subtypes of muscle-invasive bladder cancer.

02-07-2020

Nature communications

Multiple low dose therapy as an effective strategy to treat EGFR inhibitor-resistant NSCLC tumours.

22-06-2020

Cancer research

Endonuclease FEN1 Coregulates ERα Activity and Provides a Novel Drug Interface in Tamoxifen-Resistant Breast Cancer.

15-05-2020

Oncogene

Integrative analysis of genomic amplification-dependent expression and loss-of-function screen identifies ASAP1 as a driver gene in triple-negative breast cancer progression.

01-05-2020

PloS one

Approximating multivariate posterior distribution functions from Monte Carlo samples for sequential Bayesian inference.

14-03-2020

Oncoimmunology

Response of metastatic mouse invasive lobular carcinoma to mTOR inhibition is partly mediated by the adaptive immune system.

03-03-2020

The EMBO journal

In situ CRISPR-Cas9 base editing for the development of genetically engineered mouse models of breast cancer.

02-03-2020

Translational oncology

RUNX2/CBFB modulates the response to MEK inhibitors through activation of receptor tyrosine kinases in KRAS-mutant colorectal cancer.

01-02-2020

Endocrine-related cancer

Androgen modulation of XBP1 is functionally driving part of the AR transcriptional program.

01-02-2020

eLife

TLE3 loss confers AR inhibitor resistance by facilitating GR-mediated human prostate cancer cell growth.

19-12-2019

Proceedings of the National Academy of Sciences of the United States of America

Pancreatic cancer organoids recapitulate disease and allow personalized drug screening.

09-12-2019

Nature communications

CD4⁺ T cell help creates memory CD8⁺ T cells with innate and help-independent recall capacities.

04-12-2019

European journal of radiology

Are contralateral parenchymal enhancement on dynamic contrast-enhanced MRI and genomic ER-pathway activity in ER-positive/HER2-negative breast cancer related?

01-12-2019

Nature communications

Genomic data integration by WON-PARAFAC identifies interpretable factors for predicting drug-sensitivity in vivo.

06-11-2019

Science translational medicine

Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients.

09-10-2019

Bioinformatics (Oxford, England)

PRECISE: a domain adaptation approach to transfer predictors of drug response from pre-clinical models to tumors.

15-07-2019

Nature medicine

Publisher Correction: Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial.

01-07-2019

Haematologica

Lysine specific demethylase 1 inactivation enhances differentiation and promotes cytotoxic response when combined with all-trans retinoic acid in acute myeloid leukemia across subtypes.

01-06-2019

Nature medicine

Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial.

01-06-2019

Cell

Identifying Epistasis in Cancer Genomes: A Delicate Affair.

30-05-2019

Nature communications

Multiplexed Cas9 targeting reveals genomic location effects and gRNA-based staggered breaks influencing mutation efficiency.

08-04-2019

Molecular cancer therapeutics

Inhibition of the Replication Stress Response Is a Synthetic Vulnerability in SCLC That Acts Synergistically in Combination with Cisplatin.

01-04-2019

Cancers

Genetic Factors Associated with a Poor Outcome in Head and Neck Cancer Patients Receiving Definitive Chemoradiotherapy.

29-03-2019

Life science alliance

Optimized ChIP-seq method facilitates transcription factor profiling in human tumors.

01-02-2019

Nature communications

Comparative oncogenomics identifies combinations of driver genes and drug targets in BRCA1-mutated breast cancer.

23-01-2019

Briefings in bioinformatics

Principal component analysis of binary genomics data.

18-01-2019

Bioinformatics (Oxford, England)

Modelling signalling networks from perturbation data.

01-12-2018

Genome medicine

A role for the unfolded protein response stress sensor ERN1 in regulating the response to MEK inhibitors in KRAS mutant colon cancers.

27-11-2018

Nature communications

Integrative epigenetic taxonomy of primary prostate cancer.

21-11-2018

PloS one

Role of variant allele fraction and rare SNP filtering to improve cellular DNA repair endpoint association.

09-11-2018

The Journal of pathology

Consensus molecular subtype classification of colorectal adenomas.

01-11-2018

Molecular & cellular proteomics : MCP

A System-wide Approach to Monitor Responses to Synergistic BRAF and EGFR Inhibition in Colorectal Cancer Cells.

01-10-2018

Cancer research

Transcriptomics and Transposon Mutagenesis Identify Multiple Mechanisms of Resistance to the FGFR Inhibitor AZD4547.

01-10-2018

PLoS computational biology

Molecular characterization of breast and lung tumors by integration of multiple data types with functional sparse-factor analysis.

01-10-2018

Bioinformatics (Oxford, England)

Comparative Network Reconstruction using mixed integer programming.

01-09-2018

Bioinformatics (Oxford, England)

iTOP: inferring the topology of omics data.

01-09-2018

Cell reports

Nuclear Receptor Nur77 Limits the Macrophage Inflammatory Response through Transcriptional Reprogramming of Mitochondrial Metabolism.

21-08-2018

JCO precision oncology

Evaluation of the HER/PI3K/AKT Family Signaling Network as a Predictive Biomarker of Pathologic Complete Response for Patients With Breast Cancer Treated With Neratinib in the I-SPY 2 TRIAL.

16-08-2018

Open biology

Mouse models in the era of large human tumour sequencing studies.

01-08-2018

Cancer research

Integrative Modeling Identifies Key Determinants of Inhibitor Sensitivity in Breast Cancer Cell Lines.

01-08-2018

Molecular oncology

Loss of androgen receptor signaling in prostate cancer-associated fibroblasts (CAFs) promotes CCL2- and CXCL8-mediated cancer cell migration.

01-08-2018

Cell research

MAP3K1 and MAP2K4 mutations are associated with sensitivity to MEK inhibitors in multiple cancer models.

01-07-2018

A network analysis to identify mediators of germline-driven differences in breast cancer prognosis.

Loss of p53 triggers WNT-dependent systemic inflammation to drive breast cancer metastasis.

Breast adipocyte size associates with ipsilateral invasive breast cancer risk after ductal carcinoma in situ.

Epigenetic and transcriptional analysis reveals a core transcriptional program conserved in clonal prostate cancer metastases.

Correction to: A role for the unfolded protein response stress sensor ERN1 in regulating the response to MEK inhibitors in KRAS mutant colon cancers.

Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial.

Functional Categorization of BRCA1 Variants of Uncertain Clinical Significance in Homologous Recombination Repair Complementation Assays.

Radiogenomic Analysis of Breast Cancer by Linking MRI Phenotypes with Tumor Gene Expression.

Epigenetic profiling demarcates molecular subtypes of muscle-invasive bladder cancer.

Multiple low dose therapy as an effective strategy to treat EGFR inhibitor-resistant NSCLC tumours.

Endonuclease FEN1 Coregulates ERα Activity and Provides a Novel Drug Interface in Tamoxifen-Resistant Breast Cancer.

Integrative analysis of genomic amplification-dependent expression and loss-of-function screen identifies ASAP1 as a driver gene in triple-negative breast cancer progression.

Approximating multivariate posterior distribution functions from Monte Carlo samples for sequential Bayesian inference.

Response of metastatic mouse invasive lobular carcinoma to mTOR inhibition is partly mediated by the adaptive immune system.

In situ CRISPR-Cas9 base editing for the development of genetically engineered mouse models of breast cancer.

RUNX2/CBFB modulates the response to MEK inhibitors through activation of receptor tyrosine kinases in KRAS-mutant colorectal cancer.

Androgen modulation of XBP1 is functionally driving part of the AR transcriptional program.

TLE3 loss confers AR inhibitor resistance by facilitating GR-mediated human prostate cancer cell growth.

Pancreatic cancer organoids recapitulate disease and allow personalized drug screening.

CD4+ T cell help creates memory CD8+ T cells with innate and help-independent recall capacities.

Are contralateral parenchymal enhancement on dynamic contrast-enhanced MRI and genomic ER-pathway activity in ER-positive/HER2-negative breast cancer related?

Genomic data integration by WON-PARAFAC identifies interpretable factors for predicting drug-sensitivity in vivo.

Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients.

PRECISE: a domain adaptation approach to transfer predictors of drug response from pre-clinical models to tumors.

Publisher Correction: Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial.

Lysine specific demethylase 1 inactivation enhances differentiation and promotes cytotoxic response when combined with all-trans retinoic acid in acute myeloid leukemia across subtypes.

Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial.

Identifying Epistasis in Cancer Genomes: A Delicate Affair.

Multiplexed Cas9 targeting reveals genomic location effects and gRNA-based staggered breaks influencing mutation efficiency.

Inhibition of the Replication Stress Response Is a Synthetic Vulnerability in SCLC That Acts Synergistically in Combination with Cisplatin.

Genetic Factors Associated with a Poor Outcome in Head and Neck Cancer Patients Receiving Definitive Chemoradiotherapy.

Optimized ChIP-seq method facilitates transcription factor profiling in human tumors.

Comparative oncogenomics identifies combinations of driver genes and drug targets in BRCA1-mutated breast cancer.

Principal component analysis of binary genomics data.

Modelling signalling networks from perturbation data.

A role for the unfolded protein response stress sensor ERN1 in regulating the response to MEK inhibitors in KRAS mutant colon cancers.

Integrative epigenetic taxonomy of primary prostate cancer.

Role of variant allele fraction and rare SNP filtering to improve cellular DNA repair endpoint association.

Consensus molecular subtype classification of colorectal adenomas.

A System-wide Approach to Monitor Responses to Synergistic BRAF and EGFR Inhibition in Colorectal Cancer Cells.

Transcriptomics and Transposon Mutagenesis Identify Multiple Mechanisms of Resistance to the FGFR Inhibitor AZD4547.

Molecular characterization of breast and lung tumors by integration of multiple data types with functional sparse-factor analysis.

Comparative Network Reconstruction using mixed integer programming.

iTOP: inferring the topology of omics data.

Nuclear Receptor Nur77 Limits the Macrophage Inflammatory Response through Transcriptional Reprogramming of Mitochondrial Metabolism.

Evaluation of the HER/PI3K/AKT Family Signaling Network as a Predictive Biomarker of Pathologic Complete Response for Patients With Breast Cancer Treated With Neratinib in the I-SPY 2 TRIAL.

Mouse models in the era of large human tumour sequencing studies.

Integrative Modeling Identifies Key Determinants of Inhibitor Sensitivity in Breast Cancer Cell Lines.

Loss of androgen receptor signaling in prostate cancer-associated fibroblasts (CAFs) promotes CCL2- and CXCL8-mediated cancer cell migration.

MAP3K1 and MAP2K4 mutations are associated with sensitivity to MEK inhibitors in multiple cancer models.

This site uses cookies

CD4⁺ T cell help creates memory CD8⁺ T cells with innate and help-independent recall capacities.